Oral piritrexim--a phase II study in patients with advanced soft tissue sarcoma.

Suppr

超能文献

作者信息

Schiesel J D, Carabasi M, Magill G, Casper E, Cheng E, Marks L, Feyzi J, Clendeninn N J, Smalley R V

机构信息

Synertron, Inc., Madison, WI.

出版信息

Invest New Drugs. 1992 Jul;10(2):97-8. doi: 10.1007/BF00873124.

DOI:10.1007/BF00873124

PMID:1500271

Abstract

摘要

相似文献

Oral piritrexim--a phase II study in patients with advanced soft tissue sarcoma.

Invest New Drugs. 1992 Jul;10(2):97-8. doi: 10.1007/BF00873124.

Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma.

Cancer Chemother Pharmacol. 1991;28(3):223-5. doi: 10.1007/BF00685515.

Phase II trial of 10-EDAM in advanced soft tissue sarcoma. A study of the Canadian Sarcoma Group and the National Cancer Institute of Canada Clinical Trials Group.

Ann Oncol. 1994 Oct;5(8):766-8. doi: 10.1093/oxfordjournals.annonc.a058985.

Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma Group.

Eur J Cancer. 1992;28A(4-5):855-7. doi: 10.1016/0959-8049(92)90132-l.

A multicentre 12-week open study of a lipid-soluble folate antagonist, piritrexim in severe psoriasis.

Br J Dermatol. 1993 Nov;129(5):584-9. doi: 10.1111/j.1365-2133.1993.tb00489.x.

Phase II trial of oral piritrexim (BW301U) in patients with stage III non-small cell lung cancer.

Cancer Treat Rep. 1987 Jul-Aug;71(7-8):763-4.

Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.口服匹立昔明用于标准化疗失败的晚期尿路上皮癌患者的II期开放标签研究。

Clin Genitourin Cancer. 2008 Mar;6(1):31-5. doi: 10.3816/CGC.2008.n.005.

Phase II trials of trimetrexate in advanced adult soft tissue sarcoma. Studies of the Canadian Sarcoma Group and the National Cancer Institute of Canada Clinical Trials Group.

Ann Oncol. 1991 Oct;2(9):689-90. doi: 10.1093/oxfordjournals.annonc.a058051.

Aclacinomycin A. Phase II evaluation in advanced soft tissue sarcoma.阿克拉霉素A。晚期软组织肉瘤的II期评估。

Am J Clin Oncol. 1987 Jun;10(3):237-9. doi: 10.1097/00000421-198706000-00014.

Initial clinical studies of piritrexim.

NCI Monogr. 1987(5):121-5.

引用本文的文献

From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.从甲氨蝶呤到培美曲塞及其他。抗叶酸药物的药效学和临床特性综述。

Invest New Drugs. 2006 Jan;24(1):37-77. doi: 10.1007/s10637-005-4541-1.

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder.口服匹立昔明治疗晚期、既往接受过治疗的膀胱移行细胞癌的II期试验。

Invest New Drugs. 1997;15(2):157-63. doi: 10.1023/a:1005860806635.

A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma.口服匹立昔明治疗复发性高级别（III、IV级）胶质瘤的II期研究。

Br J Cancer. 1995 Sep;72(3):766-8. doi: 10.1038/bjc.1995.407.

本文引用的文献

Selective toxicity of a new lipophilic antifolate, BW301U, for methotrexate-resistant cells with reduced drug uptake.

Cancer Res. 1985 Mar;45(3):978-82.

Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase.

NCI Monogr. 1987(5):111-20.

Initial clinical studies of piritrexim.

NCI Monogr. 1987(5):121-5.

Chemotherapy of advanced soft tissue and osteosarcomas.

Semin Oncol. 1989 Aug;16(4):297-304.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验